搜索结果


   SIRT1

靶点ID:TCMBANKGE001182


靶点别名:SIR2; SIR2L1; SIR2alpha


靶点描述:sirtuin 1


染色体:10


染色体位置:10q21.3


靶点类型:protein-coding


HERB_ID:-


HGNC_Link:14929


OMIM_Link:604479


Ensembl_Link:ENSG00000096717


   靶点对应的植物
ID 拉丁名 药名 药用植物名 功能与主治 来源 药用部位 使用民族
TCMBANKHE003717 fructus Capsici 辣椒 See Capsicum annuum. fruit
TCMBANKHE003724 Rhizoma Curcumae longae 姜黄 To eliminate blood stasis, promote the flow of qi, stimulate menstrual discharge and relieve pain./Gallstones, jaundice, leukaemia in early stage and carcinoma of uterine cervix in early stage, chronic ulcer, chronic scab, blood stasis and qi stagnation, pain in chest and abdomen and rib-side, dysmenorrhea, amenorrhea, postpartum stasis stagnation abdominal pain, wind-heat impediment pain, knocks and falls, swollen welling abscess. tuberoid

   靶点对应的化合物
化合物ID 化合物名 别名 分子式 分子质量 Smiles
TCMBANKIN000008 ergothioneine C9H15N3O2S 229.3 g/mol C[N+](C)(C)C(CC1=CNC(=S)N1)C(=O)[O-]
TCMBANKIN000065 dioscin LMST01080053; C08897; 3-O-(Rhaa1-4(Rhaa1-2)Glcb)-(25R)-spirost-5-en-3beta-ol; dioscin ; 19057-60-4; Dioscin C45H72O16 869.04 CC1CCC2(C(C3C(O2)CC4C3(CCC5C4CC=C6C5(CCC(C6)OC7C(C(C(C(O7)CO)OC8C(C(C(C(O8)C)O)O)O)O)OC9C(C(C(C(O9)C)O)O)O)C)C)C)OC1
TCMBANKIN000078 silymarin AC-20318; AKOS015965311; silymarin C25H22O10 482.4 g/mol COC1=C(C=CC(=C1)C2C(OC3=C(O2)C=C(C=C3)C4C(C(=O)C5=C(C=C(C=C5O4)O)O)O)CO)O
TCMBANKIN000109 myricanol C21H26O5 358.4 g/mol COC1=C2C=C(CCCCC(CCC3=CC2=C(C=C3)O)O)C(=C1OC)O
TCMBANKIN004686 realgar AsHS 0 S[As]
TCMBANKIN012700 coumestrol NCIMech_000078; CCRIS 7311; A-Lactone; API0002121; Tox21_200032; MolPort-003-846-031; US8552057, 3; HMS3374A07; 3,9-Dihydroxy-6H-benzofuro[3,2-c]-[1]benzopyran-6-one; 6H-Benzofuro[3,2-c][1]benzopyran-6-one,3,9-dihydroxy-; Cumostrol; CHEBI:3908; C-16836; VZ31590; LS-35394; S00280; 3,9-dihydroxy-[1]benzofuro[3,2-c]chromen-6-one; MFCD00016885; SMP2_000163; DSSTox_RID_76572; 27885_FLUKA; 6H-Benzofuro[3, 3,9-dihydroxy-; 5-19-06-00405 (Beilstein Handbook Reference); BRN 0266702; 479-13-0; NSC22842; 3-Benzofurancarboxylic acid, 2-(2,4-dihydroxyphenyl)-6-hydroxy-, delta-lactone; C10205; 3,9-dihydroxy-[1]benzoxolo[3,2-c]chromen-6-one; AC1NQYXV; 3-Benzofurancarboxylic acid, 2-(2,4-dihydroxyphenyl)-6-hydroxy-, delta-lactone (6CI); NCGC00018124-01; DSSTox_CID_2399; CTK8F8799; Coumestrol, >=95.0% (HPLC); NCI60_001863; 4CN-2508; ZZIALNLLNHEQPJ-UHFFFAOYSA-N; BIDD:ER0114; NCGC00018124-03; 3,9-Dihydroxy-6H-[1]benzofuro[3,2-c]chromen-6-one #; 6H-Benzofuro(3,2-c)(1)benzopyran-6-one, 3,9-dihydroxy-; A1-00298; NSC 22842; 3,9-Dihydroxy-6H-benzofuro(3,2-c)(1)benzopyran-6-one; CCG-35536; NCGC00018124-06; 3,9-bis(oxidanyl)-[1]benzofuro[3,2-c]chromen-6-one; ZINC1219; NCGC00257586-01; 3,9-Dihydroxy-benzo[4,5]furo[3,2-c]chromen-6-one; AIDS011954; SCHEMBL22012; UNII-V7NW98OB34; 3-Benzofurancarboxylic acid, 2-(2,4-dihydroxyphenyl)-6-hydroxy-, .delta.-lactone; 6H-Benzofuro[3,2-c][1]benzopyran-6-one, 3,9-dihydroxy-; MLS000069446; CCG-36200; LMPK12090018; 3-Benzofurancarboxylic acid,4-dihydroxyphenyl)-6-hydroxy-, .delta.-lactone; 7,12-Dihydroxycoumestan; CS-6343; D02DML; CHEMBL30707; 3,9-dihydroxy-6-benzofurano[3,2-c]chromenone; ZINC00001219; 5,14-dihydroxy-8,17-dioxatetracyclo[8.7.0.0^{2,7}.0^{11,16}]heptadeca-1(10),2,4,6,11(16),12,14-heptaen-9-one; Oprea1_222511; MLS000738006; EINECS 207-525-6; 3,9-Dihydroxycoumestan; Coumestrol, BioReagent, suitable for fluorescence, >=97.5% (HPLC); A827386; DTXSID6022399; CAS-479-13-0; FT-0603177; ST50320052; 2-(2,4-Dihydroxyphenyl)-6-hydroxy-3-benzofurancarboxylic Acid ; 3,9-dihydroxybenzofurano[3,2-c]chromen-6-one; 3,9-dihydroxybenzo[d]chromeno[4,3-b]furan-6-one; NCGC00023462-03; AIDS-011954; V0359; Cumoestrol; DSSTox_GSID_22399; Cumoesterol; NCGC00018124-05; Coumestrol; NCGC00018124-04; V7NW98OB34; ZB000278; 3,9-Dihydroxy-6H-[1]benzofuro[3,2-c]chromen-6-one; ST5320052; AN-6463; Cumestrol; NCGC00023462-04; NCGC00018124-02; CC-25990; 6H-Benzofuro(3,2-c)(1)benzopyran-6-one, 3,9-dihdyroxy-; NSC-22842; 3,9-dihydroxybenzofuro[3,2-c]chromen-6-one; AKOS028111776; HMS2235B05; Coumesterol; COUMESTROL; BDBM23451; SMR000059001; HY-N2335; 27883_FLUKA C15H8O5 268.22 C1=CC2=C(C=C1O)OC3=C2C(=O)OC4=C3C=CC(=C4)O
TCMBANKIN014187 seo-wenyujinacid B C2H6OS or HSCH2CH2OH C(CS)O
TCMBANKIN031363 dimethyl sulfoxide C2H6OS 78.14 g/mol CS(=O)C
TCMBANKIN036827 xanthohumol CHEBI:134289; xanthohumol(1-); 2',4,4'-trihydroxy-6'-methoxy-3-prenylchalcone; 3-hydroxy-6-[(2E)-3-(4-hydroxyphenyl)prop-2-enoyl]-5-methoxy-2-(3-methylbut-2-en-1-yl)phenolate C21H22O5 354.4 CC(=CCC1=C(C(=C(C=C1O)OC)C(=O)C=CC2=CC=C(C=C2)O)O)C
TCMBANKIN036853 catalpol Catalpol; LMPR01020108; beta-D-Glucopyranoside, 1a,1b,2,5a,6,6a-hexahydro-6-hydroxy-1a-(hydroxymethyl)oxireno(4,5)cyclopenta(1,2-c)pyran-2-yl, (1aS-(1aalpha,1bbeta,2beta,5abeta,6beta,6aalpha))-; 2415-24-9; Catalpinoside; NCGC00163523-01; beta-D-Glucopyranoside, 1a,1b,2,5a,6,6a-hexahydro-6-hydroxy- 1a-(hydroxymethyl)oxireno(4,5)cyclopenta(1,2-c)pyran-2-yl, (1aS-(1a-alpha,1b-beta,2-beta,5a-beta,6-beta,6a-alpha))-; Catalposide, des-p-hydroxybenzoyl-; De(p-hydroxybenzoyl)catalposide; (1AS-(1aalpha,1bbeta,2beta,5abeta,6beta,6aalpha))-1a,1b,2,5a,6,6a-hexahydro-6-hydroxy-1a-(hydroxymethyl)oxireno(4,5)cyclopenta(1,2-c)pyran-2-yl-beta-D-glucopyranoside; C09773; EINECS 219-324-0 C15H22O10 362.33 C1=COC(C2C1C(C3C2(O3)CO)O)OC4C(C(C(C(O4)CO)O)O)O
TCMBANKIN038032 formononetin Oprea1_815287; AIDS027672; 7-hydroxy-3-(4-methoxyphenyl)-4H-benzopyran-4-one; Isoflavone, 7-hydroxy-4'-methoxy- (8CI); NCI60_042081; NCGC00095207-03; Oprea1_139748; NCIOpen2_005983; SDCCGMLS-0066428.P001; CHEBI:18088; TNP00176; 485-72-3; Formononetol; Isoflavone, 7-hydroxy-4'-methoxy-; 7-hydroxy-3-(4-methoxyphenyl)chromone; Spectrum2_000560; Formononetin; NSC 93360; EINECS 207-623-9; 47752_FLUKA; KBio2_000853; 7-Hydroxy-3-(4-methoxyphenyl)-4-benzopyrone; Spectrum5_000258; KBio3_001519; NSC93360; KBioSS_000853; Spectrum_000373; SPECTRUM102007; KBio2_005989; Biochanin B; KBioGR_001878; NCGC00017269-01; 7-Hydroxy-3-(4′-methoxyphenyl)-4H-benzopyran-4-one; formononetin ; 7-hydroxy-4'-methoxy-isoflavone; BSPBio_002299; ZINC00113304; 4H-1-Benzopyran-4-one, 7-hydroxy-3-(4-methoxyphenyl)- (9CI); SBB016445; Spectrum3_000660; 7-hydroxy-3-(4-methoxyphenyl)-4H-chromen-4-one; Spectrum4_001429; DivK1c_006319; KBio2_003421; SPBio_000639; NCGC00095207-01; KBio1_001263; AIDS-027672; 7-Hydroxy-4'-methoxyisoflavone; C00858; 4H-1-Benzopyran-4-one, 7-hydroxy-3-(4-methoxyphenyl)-; NCGC00095207-02; SpecPlus_000223 C16H12O4 268.264 C1([H])=C(c2c([H])c([H])c(OC([H])([H])[H])c([H])c2[H])C(c3c(O1)c([H])c(O[H])c([H])c3[H])=O
TCMBANKIN042961 silybin b Silybin B; Silybum marianum; I14-4850; (2R,3R)-3,5,7-trihydroxy-2-((2S,3S)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)chroman-4-one; (2S,3S)-2,3-Dihydro-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-6-[(2R,3R)-3,5,7-trihydroxy-4-oxobenzopyran-2-yl]benzodioxin; Milk thistle [NF]; CCRIS 7096; LS41186; (2R,3R)-3,5,7-trihydroxy-2-[(2S,3S)-3-(4-hydroxy-3-methoxy-phenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]chroman-4-one; 2717AH; Milk Thistle (Silybum marianum) Extract or Powder; 2-(2,3-Dihydro-2-(4-Hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-1,4-benzodioxin-6-yl)-2,3-dihydro-3,5,7-trihydroxy-4h-1-benzopyran-4- one; SCHEMBL751461; PRX-321; UNII-4RKY41TBTF component SEBFKMXJBCUCAI-WAABAYLZSA-N; (2R,3R)-3,5,7-Trihydroxy-2-[(2S,3S)-3-(4-hydroxy-3-methoxyphenyl)-2-hydroxymethyl-2,3-dihydrobenzo[1,4]dioxin-6-yl]-4-chromanone; (2R,3R)-3,5,7-TRIHYDROXY-2-[(2S,3S)-3-(4-HYDROXY-3-METHOXYPHENYL)-2-(HYDROXYMETHYL)-2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL]-2,3-DIHYDRO-1-BENZOPYRAN-4-ONE; AC1LU7MH; ZINC1530850; Milk Thistle (Silybum marianum) Extract or Powder [seed]; 853OHH1429; (2R,3R)-3,5,7-trihydroxy-2-[(2S,3S)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one; CHEMBL592675; (2r,3r)-2-[(2s,3s)-2,3-dihydro-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-1,4-benzodioxin-6-yl]-2,3-dihydro-3,5,7-trihydroxy-4h-1-benzopyran-4-one; Flavobion; DTXSID30858697; MolPort-039-139-345; Wild Artichoke; Legalon 70; Milk thistle; U946SH95EE; Legalon; UNII-853OHH1429; Silybin B, analytical standard; J-505458; D0C5VQ; AKOS015912848; UNII-U946SH95EE; 142797-34-0; SILYMARIN; SEBFKMXJBCUCAI-WAABAYLZSA-N; BDBM50088491; (2R,3R)-3,5,7-trihydroxy-2-[(2S,3S)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydro-4H-chromen-4-one; Silymarin + Melatonin C25H22O10 482.4 g/mol COC1=C(C=CC(=C1)C2C(OC3=C(O2)C=C(C=C3)C4C(C(=O)C5=C(C=C(C=C5O4)O)O)O)CO)O
TCMBANKIN057905 ferrum iron Fe 55.84 g/mol [Fe]
TCMBANKIN057911 se selenium H2Se 78.97 g/mol [Se]
TCMBANKIN058076 myricetin 3,3′,4′,5,5′,7-Hexahydroxyflavone; Lopac0_000740; EU-0100740; Myricetin; SPBio_002509; NCGC00015697-01; CAS-529-44-2; C10107; TNP00286; CHEBI:58395; S00115; NSC407290; ST057235; KBio2_001981; MYC; EINECS 208-463-2; 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-4-chromenone; NCI60_003870; 2-(3,4,5-TRIHYDROXYPHENYL)-3,5,7-TRIHYDROXY-4H-1-BENZOPYRAN-4-ONE; Myricitin; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-; Cannabiscetin; 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)chromone; ZINC03860925; myricetin ; BSPBio_000570; NSC-407290; CHEBI:18152; Prestwick_342; Spectrum5_000692; M6760_SIGMA; 5,7-dihydroxy-4-oxo-2-(3,4,5-trihydroxyphenyl)-4H-chromen-3-olate; NCGC00094083-04; 3,3',4,4',5',7-Hexahydro-2-phenyl-4H-chromen-4-one; ACon1_000267; Prestwick2_000465; NCGC00015697-02; 3,3',4',5,5',7-Hexahydroxyflavone; CCRIS 5838; FLAVONE, 3,3',4',5,5',7-HEXAHYDROXY-; 70050_FLUKA; KBio2_007117; AIDS-001411; 529-44-2; 5-18-05-00670 (Beilstein Handbook Reference); KBioGR_001884; 3,5,7-TRIHYDROXY-2-(3,4,5-TRIHYDROXYPHENYL)-4H-CHROMEN-4-ONE; Prestwick3_000465; KBio2_004549; Prestwick1_000465; Myricetol; NSC 407290; KBioSS_001981; AIDS001411; NCGC00015697-03; BRN 0332331; Lopac-M-6760; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)- (9CI); myricetin(1-); NCGC00094083-02; SpecPlus_000531; BPBio1_000628; 3,5,7,3',4',5'-Hexahydroxyflavone; 3,3'4'5,5'7-hexOH-Flavone; DivK1c_006627; MEGxp0_000357; Spectrum_001501; 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)chromen-4-one; Prestwick0_000465; 3,5,7-Trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-1-benzopyran-4-one; KBio1_001571; Spectrum4_001272; HY-15097; NCGC00015697-06; SPBio_002509; NCGC00015697-01; ST057235; KBio2_001981; 3,7,3',4',5'-Hexahydroxyflavone; Q-100601; LP00740; IKMDFBPHZNJCSN-UHFFFAOYSA-N; AN-939; 2-(3,4,5-TRIHYDROXYPHENYL)-3,5,7-TRIHYDROXY-4H-1-BENZOPYRAN-4-ONE; M-1214; NCGC00094083-01; HMS1569M12; NCGC00015697-13; CM0160; 3,5,7-Trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-chromen-4-one; NSC-407290; BS0289; 4CN-1085; MCULE-6299186219; SR-01000076005-1; HSDB 7682; KS-00000GOF; 529-44-2; KBioGR_001884; LS-69005; BRN 0332331; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)- (9CI); AKOS015903103; BPBio1_000628; 3,5,7,3',4',5'-Hexahydroxyflavone; C07E0ED2-ABF6-4BD3-A2B2-A98CAEF20FD1; NCGC00015697-05; DivK1c_006627; DB02375; NCGC00015697-10; Flavone,3',4',5,5',7-hexahydroxy-; Spectrum4_001272; MolPort-001-740-532; MLS006010718; TNP00286; CCG-204825; Myricetin (Cannabiscetin); Myricetin, >=96.0%, crystalline; KS-5268; SR-01000076005; NCI60_003870; AB0149714; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-; BIDD:PXR0079; SMR001233193; HMS3262C22; I14-19097; BSPBio_000570; Spectrum5_000692; 3,3 ,4 ,5,5 ,7-Hexahydroxyflavone; NCGC00094083-04; 3,3',4,4',5',7-Hexahydro-2-phenyl-4H-chromen-4-one; FLAVONE, 3,3',4',5,5',7-HEXAHYDROXY-; NCGC00094083-03; 529M442; NCGC00015697-09; 3,3',4',5,5',7-hexahydroxy-(8CI)- flavone; KBioSS_001981; cid_5281672; NCGC00015697-03; BBL023468; NCGC00094083-02; NCGC00179517-02; SpecPlus_000531; BC201817; HMS2231L04; BG01607805; A829320; NCGC00179517-01; 3,5,7-Trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-1-benzopyran-4-one; KBio1_001571; FT-0672573; STL284709; REGID_for_CID_5281672; S00115; myricetin; 3,5,7-Trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-chromen-4-one #; EINECS 208-463-2; MFCD00006827; AK111247; CHEBI:18152; GL5441; NCGC00261425-01; BIDD:ER0142; s2326; ACon1_000267; Prestwick2_000465; CCRIS 5838; KBio2_007117; 4H-1-Benzopyran-4-one,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-; MLS002153825; Prestwick1_000465; Prestwick3_000465; Bio-0838; KBio2_004549; NCGC00015697-07; Myricetol; Lopac-M-6760; BDBM15236; HMS2096M12; Myricetin, >=96.0% (HPLC); MEGxp0_000357; Spectrum_001501; 76XC01FTOJ; TR-018746; Prestwick0_000465; ST24041172; M 6760; AJ-46397; Lopac0_000740; EU-0100740; CAS-529-44-2; C10107; NSC407290; Myricetin from Myrica cerifera leaf and bark; 4gqr; 2o63; AC-4533; MYC; NCGC00015697-08; N1850; Myricitin; Cannabiscetin; D0T3PW; HMS3656I05; Tox21_500740; NCGC00015697-04; NCGC00015697-12; DTXSID8022400; Prestwick_342; 3,5,7-tris(oxidanyl)-2-[3,4,5-tris(oxidanyl)phenyl]chromen-4-one; CS-6221; M2131; ZINC3874317; BRD-K43149758-001-04-5; CHEBI: 18152; 3,3',4',5,5',7-hexOH-Flavone; NCGC00015697-02; 3,3',4',5,5',7-Hexahydroxyflavone; Myricetin, analytical standard; UNII-76XC01FTOJ; NSC 407290; LMPK12110001; AX8140581; AC1NQYV4; SCHEMBL19302; 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-1-benzopyran-4-one; SR-01000076005-6; CHEMBL164; NCGC00015697-11; 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)chromen-4-one; Myricetin, primary pharmaceutical reference standard; 3,3',4',5,5',7-hexahydroxyflavone C15H10O8 318.23 g/mol C1=C(C=C(C(=C1O)O)O)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O
TCMBANKIN058122 piceatannol (e)-piceatannol; NCGC00015794-01; 5-[(Z)-2-(3,4-dihydroxyphenyl)ethenyl]benzene-1,3-diol; 5-[(Z)-2-(3,4-dihydroxyphenyl)vinyl]benzene-1,3-diol; Lopac-P-0453; PIT; e-piceatannol; (e)-piceatannol; 5-[(Z)-2-(3,4-dihydroxyphenyl)vinyl]resorcinol; NCGC00094226-05; 5-[(E)-2-(3,4-dihydroxyphenyl)vinyl]resorcinol; KBio3_000859; IDI1_002155; 3,3',4,5'-Tetrahydroxystilbene; 3,3',4,5'-Stilbenetetrol; C05901; EU-0100915; NSC 622471; 1,2-Benzenediol, 4-[2-(3,5-dihydroxyphenyl)ethenyl]-, (E)-; 3,3',4'5-Tetrahydroxystilbene; 5-[2-(3,4-dihydroxyphenyl)ethenyl]benzene-1,3-diol; NSC365798; Lopac0_000915; 5-[2-(3,4-dihydroxyphenyl)vinyl]benzene-1,3-diol; 5-[2-(3,4-dihydroxyphenyl)vinyl]resorcinol; MEGxp0_000245; KBio2_000460; SMP2_000263; trans-3,3′,4,5′-Tetrahydroxystilbene; 1,2-Benzenediol, 4-(2-(3,5-dihydroxyphenyl)ethenyl)-; 21100-92-5; trans-3,3',4,5'-Tetrahydroxystilbene; 5-[(E)-2-(3,4-dihydroxyphenyl)ethenyl]benzene-1,3-diol; AIDS-160223; (E)-4-[2-(3,5Dihydroxyphenyl)ethenyl]1,2-benzenediol; Piceatannol; NSC 365798; 4339-71-3; E-Piceatannol; 3-Hydroxyresveratol; 4-[(1E)-2-(3,5-dihydroxyphenyl)ethenyl]benzene-1,2-diol; KBio2_005596; 10083-24-6; NCGC00094226-04; BiomolKI2_000031; 4-[(E)-2-(3,5-dihydroxyphenyl)vinyl]benzene-1,2-diol; KBioGR_000460; Bio2_000880; KBioSS_000460; NSC622471; KBio2_003028; 5-[(E)-2-(3,4-dihydroxyphenyl)vinyl]benzene-1,3-diol; KBio3_000860; 3,5,3',4'-Tetrahydroxystilbene; 1,2-Benzenediol, {4-[2-(3,} 5-dihydroxyphenyl)ethenyl]-, (E)-; BSPBio_001120; NCGC00094226-02; NCI60_003368; 1,2-Benzenediol, 4-(2-(3,5-dihydroxyphenyl)ethenyl)-, (E)-; Astringinine; P0453_SIGMA; BiomolKI_000023; AIDS160223; CHEBI:28814; 4-(2-(3,5-Dihydroxyphenyl)vinyl)-1,2-benzenediol; Bio2_000400; 3,3′,4,5′-Tetrahydroxy-trans-stilbene; K00089; ZINC00014036 C14H12O4 244.24 g/mol C1=CC(=C(C=C1C=CC2=CC(=CC(=C2)O)O)O)O
TCMBANKIN058158 Dan phenolic acid I C26H22O10 C1=CC(=C(C=C1CC(C(=O)O)OC(=O)C=CC2=C(C(=C(C=C2)O)O)C=CC3=CC(=C(C=C3)O)O)O)O
TCMBANKIN058205 trans-resveratrol (E)-1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; SRT501; AX8004672; DB02709; RP17549; NCGC00017352-05; NCGC00017352-13; NCGC00017352-19; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; 4CN-0696; I06-0437; 3,4',5-Trihydroxy-trans-stilbene; (E)-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; s1396; HMS1990H15; SAM001246888; CPD000058206; CU-01000001503-3; BPBio1_000479; NCGC00024003-14; (E)-5-(p-Hydroxystyryl)resorcinol; FT-0082623; Tox21_501111; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 01R360; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Tox21_303376; MLS001055357; NCGC00024003-13; GP5884; A827984; resveratrol; NCGC00017352-09; NCGC00017352-15; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; NCGC00024003-11; D0U3EP; ACN-034773; ST057251; EU-0101111; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1; HY-16561; N1848; ACT09778; NCGC00017352-17; BRD-K80738081-001-09-6; KUC104385N; 3,4',5-Trihydroxy-trans-stilbene 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol; LUKBXSAWLPMMSZ-OWOJBTEDSA-N; STL; MLS001424228; 5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzoldiol; 5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzenediol; HMS1569F17; Resveratrol, Vetec(TM) reagent grade, 98%; HMS1921N04; IDI1_002152; Resvida; KB-02515; SR-01000000163-10; NCGC00017352-08; AB00052942_31; 3,5,4'-Trihydroxystilbene; trans-Stilbene-3,4',5-triol; Tox21_110257; NCGC00024003-12; trans-3,4′,5-Trihydroxystilbene; trans-3,4',5 - trihydroxystilbene; ZB000650; ZINC6787; DSSTox_RID_78898; NCGC00024003-09; 3fts; BB_NC-2570; SRT-501; ZX-AS004941; 5-[(E)-2-(4-Hydroxyphenyl)ethenyl]benzol-1,3-diol; BRD-K80738081-001-23-7; trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; NSC327430; LS-2146; (E)-5-(4-Hydroxystyryl)benzene-1,3-diol; NCGC00024003-04; DSSTox_CID_11980; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3,benzenediol; Prestwick3_000508; trans-Resveratrol, United States Pharmacopeia (USP) Reference Standard; Resveratrol, European Pharmacopoeia (EP) Reference Standard; NCGC00015894-02; ARONIS24568; STL146386; R 5010; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; AC1L9HIC; BSPBio_003461; REGID_for_CID_445154; C14H12O3; SR-01000000163-11; 501-36-0; C03582; SRT 501; NSC 327430; NSC-327430; Spectrum5_000552; AS-12413; Trans-3,4′ NCGC00024003-06; AKOS005720936; BG01529320; BBC/741; HMS1792H15; NCGC00258925-01; TL8003323; AB00052942-29; SR-01000000163-4; SR-01000000163-16; BSPBio_000435; Opera_ID_586; NC00349; 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-; ZX-AT013797; 375823-41-9; HMS3403H15; 3,4',5-Trihydroxystilbene; HMS2232A18; KSC-10-164; AN-865; LMPK13090005; AJ-08292; OR46018; R0071; CHEMBL165; BRD-K25591257-001-01-2; Resveratrol, E-; BBL028252; NCGC00024003-05; LP01111; UNII-Q369O8926L; CCG-38874; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; MFCD00133799; 2l98; BDBM23926; SGCUT00007; GP2549; Resveratrol, trans-; CC-34242; ST2408097; MLS001076538; AK-39118; HMS1362H15; NCGC00024003-07; ABP000376; SBB055452; NCGC00017352-16; trans-3,5,4'-Trihydroxystilbene3,4',5-Stilbenetrioltrans-Resveratrol(E)-5-(p-Hydroxystyryl)resorcinol(E)-5-(4-hydroxystyryl)benzene-1,3-diol; 5-[(1E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; Tox21_110257_1; BRD-K80738081-001-06-2; Resveratrol, certified reference material, TraceCERT(R); 3,4',5-Stilbenetriol; MCULE-5678456463; J10118; BSPBio_001114; HMS2052I09; Resveratrol, >=99% (HPLC); CS-1050; SCHEMBL19425; 5[(E)-2-(4-Hydroxyphenyl)-vinyl]benzene 1,3-diol; Resveratol; (E)1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; HMS3263O04; 4jaz; AB0006623; CAS-501-36-0; CCRIS 8952; MLS000069735; trans-3,4',5-trihydroxystilbene; 4qer; Tox21_201374; to_000079; SPECTRUM1502223; BC202036; API0000480; NCGC00017352-10; CHEBI:27881; NCGC00017352-24; SY014849; 3,4',5-trihydroxy-stilbene; NCGC00017352-06; PREVENTION 8 (RESVERATROL); MolPort-002-499-801; (E)-resveratrol; BCPP000091; Prestwick_619; 5-((1E)-2-(4-Hydroxyphenyl)ethenyl)-1,3-benzenediol; SMR000058206; cid_445154; Q369O8926L; Resveratrol, analytical standard; DSSTox_GSID_31980; NCGC00017352-11; AC-727; HMS2096F17; BS0159; 5-[2-(4-hydroxyphenyl)vinyl]-1,3-benzenediol; BRD-K80738081-001-10-4; NCGC00017352-12; MLS002222231; Resveratrol, natural; Lopac0_001111; BR-39118; CJ-00111; NCGC00017352-07; DTXSID4031980; CR-003; Stilbene, 2f; NCGC00017352-18; NCGC00024003-10; SC-11924; SR-01000000163-3; MLS002207121; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; NCGC00024003-00; HMS3649A20; KS-5047; 1,3-Benzenediol, 5-[(E)-2-(4-hydroxyphenyl)ethenyl]-; NCGC00017352-14; HSDB 7571; NCGC00024003-08; 533C1DA0-4104-42B5-9D32-9265F40857E4; RM-1812; REGID_for_CID_6240; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; SDCCGMLS-0002998.P003; BIK9013; NCGC00257465-01; GTPL8741; BG00606847; NCGC00261796-01; CHEBI:45713; SR-01000000163; Resveratrol, synthetic; SR-01000000163-9; Prestwick2_000508; N88795; 3,5,4'-Trihydroxy-trans-stilbene; resveratrol; 1,3-Benzenediol, 5-((1Z)-2-(4-hydroxyphenyl)ethenyl)-; cis-3,5,4'-trihydroxystilbene; AIDS025474; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; SPBio_002356; BPBio1_000479; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Spectrum4_001896; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; EU-0101111; ST057251; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1; resveratrol ; KBioSS_000454; 1684AH; Spectrum3_001821; STL; CHEBI:36002; SPBio_001513; IDI1_002152; Prestwick1_000508; 05F9DB2A-D7E6-4063-8E5B-F7842CF74A5E; 3,5,4'-Trihydroxystilbene; 3,4',5-trihydroxy stilbene; (Z)-resveratrol; 5-[(Z)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; trans-3,4′,5-Trihydroxystilbene; 31100-06-8; 5-[(1Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Cis resveratrol; SRT-501; NSC327430; 3,4′,5-Trihydroxy-trans-stilbene; Spectrum_001148; 5-[(1Z)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; NCGC00024003-04; Prestwick3_000508; NCGC00015894-02; Z-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; NCGC00017352-03; SCHEMBL1931746; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; BSPBio_003461; Bio2_000877; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1-; 31100-06-8 (DELETED); Z-Resveratrol; UNII-AUA0K06FSB; 501-36-0; C03582; AKOS025395422; KBio2_004196; KBio3_002965; Prestwick0_000508; NSC 327430; 34092_RIEDEL; KBio3_000848; NCGC00017352-02; Spectrum5_000552; MolPort-003-850-143; NCGC00024003-06; KBio2_005590; SpecPlus_000391; AC1LU7HY; AUA0K06FSB; KBioGR_000454; AIDS-025474; BSPBio_000435; cis-resveratrol; KBio2_006764; KBio2_001628; KBioGR_002457; CHEMBL87333; 3,4',5-Trihydroxystilbene; Lopac-R-5010; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; KBio2_000454; Resveratrol, (Z)-; SGCUT00007; CJ-13797; NCGC00024003-07; Resveratrol (Z)-form [MI]; NCGC00017352-01; I14-7425; DivK1c_006487; MolMap_000045; 3,4',5-Stilbenetriol; Oprea1_727238; Tocris-1418; DB-072954; NCGC00017352-04; BSPBio_001114; BDBM50131698; 434C671; LUKBXSAWLPMMSZ-UPHRSURJSA-; KBio3_000847; CAS-501-36-0; SMP1_000257; 4q93; MLS000069735; cis-5-[2-(4-Hydroxyphenyl)ethenyl]benzene-1,3-diol; ZINC00006787; (Z)-3,5,4'-trihydroxystilbene; to_000079; SPECTRUM1502223; trans-Resveratrol; R5010_SIGMA; KBio2_003022; 61434-67-1; NCGC00024003-02; NCGC00015894-01; CHEBI:27881; Resveratrol; AC-24235; (E)-resveratrol; Prestwick_619; 5-[2-(4-hydroxyphenyl)vinyl]resorcinol; SMR000058206; TNP00294; Resveratrol, Z-; ZINC12353732; Lopac0_001111; cis-3,4',5-trihydroxystilbene; NCI60_002840; 5-[(E)-2-(4-hydroxyphenyl)vinyl]resorcinol; Bio2_000397; NCGC00024003-00; (Z)-3,4',5-trihydroxystilbene; 3,5-Dihydroxy-4'-methoxystilbene; 3, 5,4'-trihydroxy-trans-stilbene; cis-3,4,5-Trihydroxystilbene; NCGC00024003-08; RM-1812; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; 5-[2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; SDCCGMLS-0002998.P003; KBioSS_001628; KBio1_001431; 5-[(Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; CHEBI:45713; Spectrum2_001497; Prestwick2_000508; 3,5,4'-Trihydroxy-trans-stilbene C14H12O3 228.24 g/mol C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O
TCMBANKIN058256 salidroside 10338-51-9; (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[2-(4-hydroxyphenyl)ethoxy]oxane-3,4,5-triol; SCHEMBL17580247; (2R,3R,4S,5S,6R)-2-[2-(4-hydroxyphenyl)ethoxy]-6-methylol-tetrahydropyran-3,4,5-triol; ACon1_000366; 2-(4-Hydroxyphenyl)ethyl beta-D-glucopyranoside; Glucopyranoside, p-hydroxyphenethyl; Rhodosin; (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[2-(4-hydroxyphenyl)ethoxy]tetrahydropyran-3,4,5-triol; MEGxp0_000478; Rhodioloside; beta-D-Glucopyranoside, 2-(4-hydroxyphenyl)ethyl; C14H20O7 300.3 g/mol C1=CC(=CC=C1CCOC2C(C(C(C(O2)CO)O)O)O)O
TCMBANKIN058266 niacinamide;nicotinamide Nicotinamide compound with [1,3,4]thiadiazol-2-yl-cyanamide; AC1MHXJ9; pyridine-3-carboxamide; 1,3,4-thiadiazol-2-ylcyanamide; LY217896 & Nicotinamide C6H6N2O 122.12 g/mol C1=CC(=CN=C1)C(=O)N
TCMBANKIN058364 IPH NCI-C50124; Phenol, liquid; Baker's P and S Liquid and Ointment; 48556_SUPELCO; Un 2812 (solution); Carbolic oil; 16018_RIEDEL; P4557_SIAL; AI3-01814; 52463_FLUKA; UN2821; Phenol, sulfurated; NSC 36808; (14C)Phenol; Phenic; 242322_SIAL; Fenolo; Phenol, chloro derivs.; 185450_SIAL; Paoscle (TN); P4682_SIAL; Fenosmoline; Phenole [German]; Phenole; PhOH; 328111_SIAL; 77614_FLUKA; acide phenique; UN2312; ST5214353; Carbolic acid, liquid; Phenol [JAN]; Liquid phenol; LS-476; P3653_SIAL; Phenol, solid [UN1671] [Poison]; NCGC00091454-03; RCRA waste number U188; WLN: QR; W322318_ALDRICH; Phenol (liquid); Phenol (or solutions with 5% or more phenol); Caswell No. 649; 16016_RIEDEL; Baker's p and s; Phenol, synthetic; Fenolo [Italian]; Phenol, pure; Phenol solution; HSDB 113; Phenyl alcohol; Oxybenzene; Izal; C15584; FEMA No. 3223; phenylalcohol; AIDS-000352; NSC36808; Phenol (TN); Phenol alcohol; 40063_SUPELCO; Phenol-UL-14C; UN 1671 (solid); 16017_RIEDEL; 33517_RIEDEL; InChI=1/C6H6O/c7-6-4-2-1-3-5-6/h1-5,7; Acide carbolique [French]; carbolic acid; Synthetic phenol; Phenyl hydroxide; Fenol [Dutch, Polish]; RCRA waste no. U188; NCGC00091454-01; P1037_SIAL; UN1671; 46344_RIEDEL; 35952_RIEDEL; Fenol; ZINC00895069; Phenol, labeled with carbon-14; Fenosmolin; Baker's P & S liquid & Ointment; Monophenol; Phenylic alcohol; 564796_ALDRICH; Monohydroxybenzene; Phenol solutions [UN2821] [Poison]; 77607_FLUKA; Phenol, molten [UN2312] [Poison]; 297437_SIGMA; P9346_SIAL; CHEBI:15882; c0128; Carbolsaure [German]; EINECS 203-632-7; Phenol (JP15/USP); Phenyl hydrate; Phenol, polymer-bound; UN 2312 (molten); D00033; EPA Pesticide Chemical Code 064001; EINECS 262-972-4; 48688_SUPELCO; Phenol, liquefied; Phenol, chlorinated; Benzene, hydroxy-; CCRIS 504; Karbolsaeure; Paoscle; Liquified Phenol; Acide carbolique; Monohydroxy benzene; P5566_SIAL; NCGC00091454-02;phenylic alcohol;NCI-C50124; 582-EP2308872A1; UN 2312; 582-EP2284148A1; 582-EP2308875A1; 582-EP2275404A1; 582-EP2292597A1; Phenol, liquid; 582-EP2315502A1; AC1Q791G; 582-EP2305689A1; NCGC00259188-01; 582-EP2295426A1; Campho-Phenique Liquid; 582-EP2380872A1; 582-EP2311464A1; 582-EP2316937A1; 3f39; 78049-EP2277868A1; Carbolsaeure; 582-EP2284157A1; J-610001; Carbolsaure; UN2821; 582-EP2305698A2; 582-EP2279750A1; 582-EP2308861A1; AJ-53232; 108-95-2; 582-EP2275395A2; MFCD00002143; 582-EP2275105A1; Phenole [German]; Phenole; AC1L1AHZ; 582-EP2286812A1; 582-EP2308877A1; Phenol, detached crystals, 99% 100g; acide phenique; 582-EP2287166A2; P1610; 582-EP2301538A1; 582-EP2301919A1; 582-EP2316470A2; Hydroxybenzene; Tox21_113463_1; 61788-41-8; 582-EP2316974A1; 14534-23-7; NCGC00091454-03; WLN: QR; Phenol, SAJ first grade, >=98.0%; 582-EP2277879A1; Phenol (or solutions with 5% or more phenol); benzenod; 582-EP2277881A1; Baker's p and s; RL00383; Phenol, pure; 582-EP2301924A1; PHENOL- D6; HSDB 113; Hydroxy-benzene; Izal; Phenol, unstabilized, purified by redistillation, >=99%; C15584; Phenol, puriss., meets analytical specification of Ph. Eur., BP, USP, >=99.5% (GC), crystalline (detached); NCGC00091454-04; 582-EP2280021A1; UN 1671 (solid); C6H6O; InChI=1/C6H6O/c7-6-4-2-1-3-5-6/h1-5,7; 582-EP2298758A1; 582-EP2272817A1; 582-EP2308848A1; Phenol solution, BioReagent, Saturated with 0.1 M citrate buffer, pH??4.3 +/- 0.2, for molecular biology; Phenol [USP:JAN]; 582-EP2289879A1; H2391; 582-EP2305649A1; 582-EP2308873A1; Phenol, LR, >=99%; AK113559; 582-EP2298753A1; NCGC00091454-07; RCRA waste no. U188; Phenol, ultrapure; 582-EP2311811A1; SMR000568492; Fenosmolin; 582-EP2302015A1; Phenylic alcohol; 78049-EP2277870A1; Pandy's reagent; 582-EP2280004A1; 582-EP2301926A1; Liquefied phenol BP; Carbolsaure [German]; EINECS 203-632-7; 8002/7/1; 582-EP2272849A1; Phenol, BioXtra, >=99.5% (GC); ISWSIDIOOBJBQZ-UHFFFAOYSA-N; 582-EP2301935A1; 582-EP2308880A1; FT-0645154; Paoscle; Phenol molten; 50356-25-7; 582-EP2295424A1; AB1002201; Benzenol; BDBM26187; Phenol, >=99%; 582-EP2311814A1; Fenol(DUTCH, POLISH); 582-EP2280003A2; 582-EP2311494A1; 1li2; 582-EP2316832A1; 1ai7; Un 2812 (solution); Carbolic oil; 582-EP2298759A1; AI3-01814; Phenol, sulfurated; 582-EP2298778A1; (14C)Phenol; 582-EP2301929A1; Phenol, PESTANAL(R), analytical standard; 582-EP2295434A2; BIDD:ER0293; NCGC00254019-01; I01-9247; 582-EP2275411A2; 582-EP2308838A1; Paoscle (TN); 582-EP2284147A2; EC 203-632-7; Fenosmoline; hydroxybenzend; PhOH; 582-EP2272813A2; 582-EP2305687A1; Phenol, detached crystals; Phenol, AR, >=99.5%; MolPort-000-871-946; Tox21_113463; PHENOL, 80% in ethanol; 582-EP2272822A1; DSSTox_RID_75955; Phenol solution, 100 mug/mL in acetonitrile, PESTANAL(R), analytical standard; Carbolic acid, liquid; Liquid phenol; 582-EP2277570A2; Phenol, >25% in a non hazardous diluent; Phenol (liquid); Phenol, for molecular biology; Caswell No. 649; 582-EP2277568A2; Phenol, synthetic; Fenolo [Italian]; 582-EP2305674A1; 4-hydroxybenzyl group; 582-EP2295429A1; 582-EP2287162A1; 78049-EP2272846A1; Phenol, p.a., ACS reagent, 99.5-100.5%; FEMA No. 3223; Phenol (TN); Phenol (JP17/USP); DTXSID5021124; 582-EP2287161A1; 582-EP2305673A1; 582-EP2295399A2; 139-02-6 (hydrochloride salt); 582-EP2305664A1; 582-EP2371811A2; 582-EP2374784A1; 582-EP2277569A2; 582-EP2305695A2; BP-30160; 582-EP2308510A1; KB-59534; 582-EP2298744A2; Phenol, natural, 97%, FG; 582-EP2295437A1; carbolic acid; 582-EP2280010A2; 582-EP2284160A1; 582-EP2287165A2; Fenol [Dutch, Polish]; UN1671; 582-EP2371807A1; Phenol, labeled with carbon-14; Phenol, United States Pharmacopeia (USP) Reference Standard; UN 2821; Liquefied phenol; Monohydroxybenzene; bmse000290; 582-EP2289892A1; 582-EP2311822A1; Cepastat lozenges; Phenol solutions; 78049-EP2292608A1; 582-EP2305625A1; 582-EP2305684A1; Phenol, polymer-bound; 582-EP2301983A1; Phenyl hydrate; UN 2312 (molten); 582-EP2280020A1; 582-EP2308878A2; Phenol, BP grade 80% aqueous solution; MCULE-9943948107; EINECS 262-972-4; KS-00000VIO; DB03255; UNII-339NCG44TV; 582-EP2311831A1; Phenol, molten [UN2312] [Poison]; Monohydroxy benzene; NCGC00091454-02; 582-EP2316833A1; LS-105199; Phenol solution, 5000 mug/mL in methanol, certified reference material; 582-EP2277567A1; Cuticura pain relieving ointment; 582-EP2277867A2; 582-EP2298742A1; 582-EP2316824A1; 582-EP2314579A1; 582-EP2305243A1; Baker's P and S Liquid and Ointment; 582-EP2372017A1; 582-EP2316829A1; F1908-0106; AN-22534; 582-EP2305627A1; ACMC-1CE2K; 582-EP2280006A1; NSC 36808; 582-EP2284169A1; Fenolo; PHENOL, ACS; 78049-EP2371806A1; DSSTox_GSID_21124; 582-EP2295428A2; 582-EP2289883A1; Liquefied phenol (TN); UN 1671; 582-EP2284146A2; 582-EP2301937A1; 582-EP2305633A1; Phenol synthetic; Phenol [JAN]; Phenolated water for disinfection; MLS001065591; Phenol solutions [UN2821] [Poison]; NSC-36808; Phenol homopolymer; Phenol, solid [UN1671] [Poison]; DSSTox_CID_1124; 582-EP2269997A2; 582-EP2311455A1; NCGC00091454-05; 582-EP2308840A1; Phenol stock solution, 100 mg/dL, standard; C00146; PHENOL REAGENT; 582-EP2301536A1; 582-EP2272972A1; 582-EP2305808A1; Phenyl alcohol; 582-EP2316836A1; 582-EP2371806A1; 582-EP2281819A1; 78049-EP2371807A1; Phenol, polymer-bound, 100-200 mesh, extent of labeling: 0.5-1.5 mmol/g loading, 1 % cross-linked with divinylbenzene; 582-EP2305648A1; 582-EP2305640A2; 582-EP2314571A2; Phenol, >=96.0% (calc. on dry substance, T); Phenol, BioUltra, for molecular biology, >=99.5% (GC); I14-62966; NA 2821; SC-26791; Phenol,industrial; Phenol for disinfection (JP17); 582-EP2374785A1; 582-EP2277872A1; Phenol polymer-bound; CS0062; 582-EP2281817A1; AKOS000119025; 582-EP2305679A1; 582-EP2275420A1; 582-EP2275403A1; 582-EP2311834A1; NCGC00091454-01; Fenol; Tox21_300042; Baker's P & S liquid & Ointment; bmse010026; Liquified Phenol, meets USP testing specifications, >=89.0%; Campho-Phenique Cold Sore Gel; CAS-108-95-2; CRISTALESDEFENOL; 582-EP2284165A1; 582-EP2314576A1; Carbolic acid liquid; 582-EP2308865A1; TEA polyphenol; 582-EP2270003A1; 582-EP2270101A1; 78049-EP2308866A1; C6H5OH; ANW-15995; D00033; 63496-48-0; AM802906; Phenosmolin; Liquefied phenol (JP17); 582-EP2311829A1; Phenol, ACS reagent; Benzene, hydroxy-; CCRIS 504; Phenol, 90% aqueous solution; Hydroxybenzene solution; 582-EP2280012A2; Acide carbolique; CTK0H5673; 582-EP2269975A2; 582-EP2277566A2; 582-EP2298776A1; 78049-EP2277869A1; Phenic alcohol; p-Hydroxy polystyrene (100-200 mesh, 0.5-1.5 mmol/g); 582-EP2295438A1; NCGC00091454-06; Phenol, solid; 582-EP2295427A1; Phenol, contains hypophosphorous as stabilizer, loose crystals, ACS reagent, >=99.0%; 582-EP2305033A1; 582-EP2275415A2; 582-EP2311808A1; 582-EP2272973A1; Phenol, JIS special grade, >=99.0%; Phenol, >=99.0%; 52009-05-9; 582-EP2314295A1; Phenic; 582-EP2298750A1; PHENOL, ULTRA PURE; 582-EP2298734A2; phenol; 582-EP2287167A1; 582-EP2284178A2; Tox21_201639; 582-EP2272935A1; 27073-41-2; 582-EP2270113A1; 582-EP2305697A2; Phenol, molten; UN2312; LS-476; 582-EP2289509A2; Phenol, puriss. p.a., ACS reagent, reag. Ph. Eur., 99.0-100.5%; IPH; PHENOL REAGE NT; 78049-EP2287158A1; Phenol solution; Oxybenzene; Phenol for disinfection (TN); 582-EP2298775A1; Campho-Phenique Gel; phenylalcohol; Phenol liquid; NSC36808; 582-EP2377842A1; Phenol alcohol; Phenol 10 microg/mL in Methanol; 4i7l; RTR-002010; hydroxy benzene; Phenol, BioUltra, for molecular biology, TE-saturated, ~73% (T); Carbolicum acidum; 582-EP2292280A1; Phenol, unstabilized, ReagentPlus(R), >=99%; 56322-06-6; 582-EP2314588A1; Acide carbolique [French]; 582-EP2274983A1; Synthetic phenol; 582-EP2289891A2; Phenyl hydroxide; Phenic acid; phenylic acid, phenyl hydroxide; MFCD03703209; 582-EP2277565A2; 2-hydroxybenzoyl group; LTBB002354; 582-EP2287158A1; Monophenol; Phenol 100 microg/mL in Methanol; 582-EP2269977A2; 582-EP2289965A1; 582-EP2286811A1; Phenol solutions [UN2821] [Poison]; 582-EP2292620A2; 582-EP2316831A1; Phenol, molten [UN2312] [Poison]; 582-EP2305696A2; 73607-76-8; ZINC5133329; 582-EP2280001A1; 582-EP2295411A1; CHEBI:15882; Phenol solution, certified reference material, 500 mug/mL in methanol; 582-EP2289896A1; 582-EP2308471A1; 339NCG44TV; 582-EP2305668A1; phenyloxidanyl; Rcra waste number U188; EPA Pesticide Chemical Code 064001; Phenol, solid [UN1671] [Poison]; 582-EP2305662A1; CHEMBL14060; 582-EP2316452A1; 97694-EP2305662A1; Phenol, liquefied; 582-EP2311824A1; Phenylic acid; Karbolsaeure; 582-EP2289868A1; Phenol, puriss., meets analytical specification of Ph. Eur., BP, USP, 99.5-100.5% (GC); Liquified Phenol; Phenol, for molecular biology, ~90% (T), liquid; Phenolated water; 582-EP2305685A1; 582-EP2292608A1; Phenol solution, BioReagent, Equilibrated with 10??mM Tris HCl, pH??8.0, 1??mM EDTA, for molecular biology;4-[5-phenyl-4,5-dihydro-3-isoxazolyl)-2-methylphenol; 2-methyl-4-(5-phenyl-4,5-dihydroisoxazol-3-yl)phenol;phenylic acid;phenol;hydroxybenzene C6H6O 94.11 g/mol C1=CC=C(C=C1)O
TCMBANKIN058519 (-)-epigallocatechin-3-gallate; (-)-epigallocatechin 3-o-gallate;epigallocatechin gallate; galloyl-l-epigallocatechol; epigallocatechin 3-gallate; (-)-epigallocatechin gallate; KBio2_000796; SpecPlus_000277; 50299_FLUKA; Spectrum3_000244; KBioGR_002002; 3,4,5-trihydroxybenzoic acid [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] ester; MLS000758300; DivK1c_006373; (−)-Epigallocatechin gallate; EGCG; SPBio_000035; (−)-cis-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol 3-gallate; KBioSS_000796; Epigallocatechin gallate; Spectrum4_001541; (-)-epigallocatechin 3-gallate; Tea catechin; AIDS000674; KBio2_005932; 3,4,5-trihydroxybenzoic acid [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3-chromanyl] ester; KBio1_001317; 989-51-5; AIDS-000674; (2R,3R)-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1[2H]-benzopyran-3,5,7-triol-3-(3,4,5-trihydroxybenzoate); KBio2_003364; Galloyl-L-epigallocatechol; SDCCGMLS-0066550.P001; (-)-Epigallocatechol gallate; ACon1_001054; Spectrum5_000102; Green tea extract; MEGxp0_001166; C09731; (-)-Epigallocatechin-3-o-gallate; Epigallocatechin 3-gallate; (-)-Epigallocatechin gallate; CCRIS 3729; Teavigo; [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] 3,4,5-trihydroxybenzoate; Spectrum2_000168; Benzoic acid, 3,4,5-trihydroxy-, (2R,3R)-3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester; (−)-cis-3,3′,4′,5,5′,7-Hexahydroxy-flavane-3-gallate; CHEBI:4806; (-)-epigallocatechin-3-gallate ; (-)-Epigallocatechin gallate (85% (-)-epigallocatechin gallate, 10% (-)-epigallocatechin, 5% (-)- epicatechin gallate); Catechin deriv.; SMR000449288; SPECTRUM210239; E4143_SIAL; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate; Spectrum_000316; (-)-EGCG; KBio3_001128; BSPBio_001628; Epigallocatechol, 3-gallate, (-)-; Epigallocatechin-3-gallate; E4268_SIAL; epigallocatechin gallate ; epigallocatechin-3-gallate; (-)epigallocatechin-3-gallate ; EGCG; 989E515; [5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] 2,3,4-trihydroxybenzoate; HMS2051K21; CS-1258; AC1L22IG; AK165605; Green tea polyphenols, Anagen; (-)-Epigallocatechin-3-O-gallate, United States Pharmacopeia (USP) Reference Standard; AKOS015918182; CAS-989-51-5; Epigallocatechin gallate, primary pharmaceutical reference standard; W-5069; (-)-cis-3,3',4',5,5',7-Hexahydroxy-flavane-3-gallate; (-)-Epigallocatechin gallate, analytical standard; Q-100914; DSSTox_RID_78830; AN-15867; DSSTox_GSID_29889; (-)-Epigallocatechol gallate; FT-0604392; NCGC00164319-04; Green tea extract; MEGxp0_001166; (-)-Epigallocatechin-3-o-gallate; Epigallocatechin 3-gallate; N1874; CHEBI:4806; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate; BG00814299; HMS3649E08; D0E9DB; Epigallocatechol, 3-gallate, (-)-; (-)-EpigallocatechinGallateHydrate; Epigallocatechin-3-gallate; AB0014381; BQM438CTEL; NC00078; ST51055716; Epigallocatechin gallate, Pharmaceutical Secondary Standard; Certified Reference Material; SpecPlus_000277; Spectrum3_000244; (2R,3R)-5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl-3,4,5-trihydroxybenzoate; MLS000758300; (-)-Epigallocatechin gallate (EGCG); CCG-38378; Gallic acid, 3-ester with epigallocatechol, (-)-; SR-01000946601-1; NCGC00164319-01; (-)-cis-3,4-Dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-1(2H)-benzopyran-3-yl Gallate; NCGC00164319-06; DSSTox_CID_567; MCULE-3341525983; Epigallocatechin monogallate, B; Tox21_303457; SAM001247031; 4awm; K791; 989-51-5; SR-01000946601; MFCD00075940; EGCG analogs; Galloyl-L-epigallocatechol; NCGC00164319-03; (-)-Epigallocatechin gallate, >=80% (HPLC), from green tea; Spectrum5_000102; CPD000449288; (-)-Epigallocatechin gallate; LMPK12030005; E0694; Teavigo; Epigallocatechin gallate analogs, Anagen; Epigallocatechin-3-monogallate; ACN-035233; Benzoic acid, 3,4,5-trihydroxy-, (2R,3R)-3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester; Sunphenon; Epigallocatechin gallate(EGCG); s2250; PF-EGCg 90; 3,4-Dihydro-5,7-dihydroxy-2R-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3R-yl-3,4,5-trihydroxybenzoate; 3,4,5-Trihydroxybenzoic acid (2R,3R)-3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester; MLS001424000; (-)-EGCG; ZINC3870412; KBio2_000796; EGCG cpd; KBioGR_002002; Benzoic acid, 3,4,5-trihydroxy-, 3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester, (2R-cis)-; EGCG, Anagen; NCGC00257243-01; Tox21_201468; L-Epigallocatechin gallate; cid_65064; SPBio_000035; BG01747388; Epigallocatechin gallate; KBioSS_000796; Spectrum4_001541; (-)-epigallocatechin 3-gallate; DB12116; EPIGALOCATECHIN GALLATE; ANTIOXIDANT MODEL (TRAMP) -EPIGALLOCATECHIN GALLATE; KBio2_005932; I14-7747; D0U2BH; MCULE-7760530136; 2kdh; Epigallocatechin gallate, Anagen; AOB2839; SDCCGMLS-0066550.P001; 863-65-0; FR-109; ST097428; ACon1_001054; LS-2197; CCRIS 3729; [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] 3,4,5-trihydroxybenzoate; Epigallocate; GTPL7002; BDBM50070942; C22H18O11; GTPs,Anagen; SCHEMBL35258; (2R,3R)-5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxybenzoate; MolPort-001-741-358; DivK1c_006373; KB-206444; SR-01000759328; Teavigo;; EGCG; (-)-EPIGALLOCATECHIN GALLATE (GREEN TEA EXTRACT); HY-13653; (-)-Epigallocatechin gallate, >=95%; NCGC00259019-01; Tea catechin; DS-9030; SR-01000759328-6; SR-01000759328-5; KDH; AC1Q5X0Z; KBio1_001317; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxyb enzoate; (2R,3R)-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1[2H]-benzopyran-3,5,7-triol-3-(3,4,5-trihydroxybenzoate); NVP-XAA 723; KBio2_003364; EBD2138593; FT-0082796; NCGC00164319-02; C09731; (-)-cis-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol 3-gallate; UNII-BQM438CTEL; DTXSID1029889; WMBWREPUVVBILR-WIYYLYMNSA-N; [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate; (-)-Epigallocatehin gallate; Spectrum2_000168; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-3-yl 3,4,5-trihydroxybenzoate; (-)-Epigallocatechin gallate (85% (-)-epigallocatechin gallate, 10% (-)-epigallocatechin, 5% (-)- epicatechin gallate); Catechin deriv.; SMR000449288; (-)-Epigallocatechin gallat; SPECTRUM210239; Epigallocic acid; Epigallocatcchin Gallate; KS-0000132O; BP-30205; CHEMBL297453; SC-47284; Spectrum_000316; 3oob; (-)-Epigallocatechin gallate, >=97.0% (HPLC); KBio3_001128; BSPBio_001628; epigallo-catechin gallate C22H18O11 458.4g/mol C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O
TCMBANKIN058706 betulin AKOS025402304; Ambotz473-98-3; betulin ; AC-7983; SCHEMBL9888462; (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13bR)-3a-(hydroxymethyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[a]chrysen-9-ol; FVWJYYTZTCVBKE-MAIYTPNSSA-N; ; Trochol; 18211-63-7; C08618; Messagenin; 473-98-3; AIDS002710; B9757_SIGMA; ZINC03978650; Prestwick3_000990; Betulin; MEGxp0_001726; AI3-62999; BSPBio_001059; Lup-20(30)-ene-3beta,28-diol; C08631; Betulinol; ACon1_000091; AIDS-002710; Lup-20(29)-ene-3beta,28-diol; BPBio1_001165; Betuline; Lup-20(29)-ene-3,28-diol, (3beta)-; NSC 4644; (3.beta.)-Lup-20(29)-ene-3,28-diol; NSC692218; EINECS 207-475-5; Betulinic alcohol; ST5411404; Trochol C30H50O2 442.7g/mol CC(=C)C1CCC2(C1C3CCC4C5(CCC(C(C5CCC4(C3(CC2)C)C)(C)C)O)C)CO
TCMBANKIN058802 cudraflavone b;Mulberrochromene CHEMBL221907; 2-(2,4-dihydroxyphenyl)-5-hydroxy-8,8-dimethyl-3-(3-methylbut-2-enyl)pyrano[5,6-g]chromen-4-one; 8-(2,4-dihydroxyphenyl)-5-hydroxy-2,2-dimethyl-7-(3-methylbut-2-en-1-yl)-2H,6H-pyrano[3,2-g]chromen-6-one; cid_5319925; 2-(2,4-dihydroxy-phenyl)-5-hydroxy-8,8-dimethyl-3-(3-methyl-but-2-enyl)-8H-pyrano[3,2-g]chromen-4-one; 2-(2,4-dihydroxyphenyl)-5-hydroxy-8,8-dimethyl-3-(3-methylbut-2-enyl)-4-pyrano[5,6-g]chromenone; BDBM50193718; MLS000697596; mulberrochromene; AC1NSYTH; cudraflavone B; 8-(2,4-dihydroxyphenyl)-5-hydroxy-2,2-dimethyl-7-(3-methylbut-2-enyl)pyrano[3,2-g]chromen-6-one; HMS2268D05; SMR000470934; CHEBI:67850; 19275-49-1; 2-(2,4-dihydroxyphenyl)-5-hydroxy-8,8-dimethyl-3-(3-methylbut-2-enyl)pyrano[3,2-g]chromen-4(8H)-one C25H24O6 420.5 g/mol CC(=CCC1=C(OC2=CC3=C(C=CC(O3)(C)C)C(=C2C1=O)O)C4=C(C=C(C=C4)O)O)C
TCMBANKIN059159 capsaicin 8-Methyl-N-vanillyl-6-nonenamide, (E)-; AKOS007930159; Bio-0615; GTPL2486; Bio2_000748; EPA Pesticide Chemical Code 070701; Zostrix HP; S07O44R1ZM; TC-030399; 360376_ALDRICH; NCGC00017337-07; Citrus Aurantium 30%; AK589917; ZOSTRIX (TN); HMS2230O23; D0U5CE; HMS1989N10; IDI1_034018; DSSTox_GSID_20241; Isodecenoic acid vanillylamide; NGX-7325; NCGC00017337-04; HMS1791N10; NCGC00090853-08; NCGC00090853-11; KBio3_000536; (E)-8-Methyl-N-vanillyl-6-nonenamide(8cl); NSC-757844; M2028_SIGMA; E-CAPSAICIN; Capsaicin, from Capsicum sp., >=50% (HPLC); (6E)-N-(4-hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide; MCULE-8056866140; Capsaicin [USP:INN]; NCGC00257869-01; 6-Nonenamide, 8-methyl-N-vanillyl-, (E)-; DB06774; trans-N-((4-Hydroxy-3-methoxyphenyl)methyl)-8-methyl-6-nonenamide; SMR000718774; KBioGR_000268; MEGxp0_001448; 6-Nonenamide, N-((4-hydroxy-3-methoxyphenyl)methyl)-8-methyl-, (E)-; Caswell No. 158; Prestwick2_000879; KBio1_000354; FEMA No. 3404; Capsaicin, analytical standard; N735; HMS3649N15; SBI-0052593.P002; AJ-26667; BRD-K50590187-001-06-6; CAS_404-86-4; NCGC00017337-02; HMS1921H11; 8-Methyl-N-vanillyl-trans-6-nonenamide; 21750_FLUKA; ZINC01530575; Vanilloid; YKPUWZUDDOIDPM-SOFGYWHQSA-N; MR3H3; (E)-N-((4-Hydroxy-3-methoxyphenyl)-methyl)-8-methyl-6-nonenamide; 6-Nonenamide, N-((4-hydroxy-3-methoxyphenyl)methyl)-8-methyl-, (6E)-; HMS1570P19; capsaicin ; Nonenamide, N-((4-hydroxy-3-methoxyphenyl)methyl)-8 -methyl-, (E)-; KBio3_000535; Zostrix (TN); KBio2_000783; 6-Nonenamide, N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-, (6E)-; NCGC00017337-06; Capsaicin, European Pharmacopoeia (EP) Reference Standard; Capsicin; N-(3-Methoxy-4-hydroxybenzyl)-8-methyl-6-nonenamide; KBioSS_000783; N-((4-Hydroxy-3-methoxyphenyl)methyl)-8-methyl-6-nonenamide, (E)-; Bitter orange extract 30%; N-(4-Hydroxy-3-methoxybenzyl)-8-methylnon-trans-6-enamide; SR-05000001861-5; Capsaicin, certified reference material, TraceCERT(R); CAPSAICIN, NATURAL; DSSTox_RID_75455; 6-Nonenamide, N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-, (E)-; Capsaicin, Pharmaceutical Secondary Standard; Certified Reference Material; N-(4-hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide; depletes Substance P; trans-8-Methyl-N-vanillyl-6-nonenamide; BDBM20461; MolPort-001-742-263; 1217899-52-9; NCGC00090853-03; SR-05000001861; Spectrum_000303; UPCMLD-DP092:001; Capsaicin, >=95%, from Capsicum sp.; Capsaicin (transdermal patch formulation, neuropathic pain); I01-2469; Nonenamide, 8-methyl-N-vanillyl-, (E)-; SR-05000001861-9; CC0144; Transacin; AC1Q46B3; SDCCGMLS-0066678.P001; SR-05000001861-6; Axsain; AN-23437; (6E)-N-{[4-hydroxy-3-(methyloxy)phenyl]methyl}-8-methylnon-6-enamide; (E)-N-(4-Hydroxy-3-methoxybenzyl); (E)8-methyl-N-vanillyl-6-Nonenamide; CCRIS 1588; Capsaicin (JAN/USP); Capsaicin (Natural); trans-Capsaicin-d3; N0C781; trans-8-Methyl-N-vanillylnon; M1149; SC-19636; (E)-N-(4-hydroxy-3-methoxy-benzyl)-8-methyl-non-6-enamide; Styptysat; HMS2097P19; NCGC00017337-11; KBio3_002417; neurotoxic; CHEMBL294199; Capsaicin (in oleoresin of capsicum); NCGC00090853-01; N-(4-hydroxy-3-methoxy-benzyl)-8-methyl-non-6-enamide; Capsaicin [USAN]; Capsicine; NCGC00017337-08; NCGC00017337-09; C06866; N-[(4-hydroxy-3-methoxy-phenyl)methyl]nonanamide; NGX-1998; Tox21_110817; SCHEMBL8086; UNII-S07O44R1ZM; NSC 56353; (E)-N-[(4-HYDROXY-3-METHOXYPHENYL)METHYL]-8-METHYL-6-NONENAMIDE; BDBM86537; LMFA08020085; N-[(4-hydroxy-3-methoxy-phenyl)methyl]-8-methyl-non-6-enamide; KBio2_002836; trans-8-methyl-N-vanillyl-6-nonenamide; NCGC00090853-06; CHEBI:94524; NCGC00090853-09; NCGC00090853-02; Bio2_000268; HMS3402N10; Prestwick_204; Prestwick3_000879; 8-Methyl-N-vanillyl-6E-nonenamide; Spectrum4_001739; 8-Methyl-N-Vanillyl-6-Nonenamide; N-[(4-Hydroxy-3-methoxyphenyl)methyl]-8-methyl-6-nonenamide; BSPBio_001548; LS-2138; Capsaicin, United States Pharmacopeia (USP) Reference Standard; KBioGR_002158; EINECS 206-969-8; Bio1_000468; SPBio_002878; KBio2_000268; MFCD00017259; Bio1_001446; nchembio862-comp2; 6-Nonenamide, (E)-N-((4-hydroxy-3-methoxy-phenyl)methyl)-8-methyl; NSC-56353; NSC757844; DTXSID9020241; Ausanil; HMS501B16; HMS2092D21; EI-125; NCGC00090853-04; AK113598; NCI-C56564; Qutenza; SR-05000001861-4; [(E)-N-(4-Hydroxy-3-methoxyphenyl)methyl]-8-methyl-6-nonenamide; (6E)-N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide; Adlea; MLS002154049; (E)-8-Methyl-N-vanillyl-6-nonenamide; Pharmakon1600-01501128; Spectrum5_000538; (e)-n-(4-hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide; 6-Nonenamide, (E)-; SCHEMBL8085; AB00053098-11; Capsaicin [in oleoresin of capsicum]; CJ-23980; NCGC00017337-12; HSDB 954; NGX 4010; CAS-404-86-4; BRN 2816484; 4CH-016296; NSC56353; IDI1_000354; RTC-030399; (E)-Capsaicin; TL8002946; NCGC00017337-05; CS-1518; Mioton; BG01597556; DivK1c_000354; 12084_FLUKA; Bio1_000957; AC-10114; AC1LU7K3; UPCMLD-DP092; N-((4-Hydroxy-3-methoxyphenyl)methyl)-8-methyl-6-nonenamide; TQ-1018; FT-0082538; Zostrix; NCGC00017337-03; AB00053098_12; SPECTRUM1501128; KS-5181; Prestwick1_000879; Capsaicin, from natural source; NCGC00017337-13; n-(4-hydroxy-3-methoxybenzyl)-8-methyl-6-nonenamide; Spectrum2_000770; NSC_2548; Prestwick0_000879; BPBio1_001053; NCGC00090853-10; C18H27NO3; NCGC00090853-12; W-5044; CAPSAICINE; SR-05000001861-1; Tox21_200315; HMS1361N10; D00250; (6E)-N-(4-Hydroxy-3-methoxybenzyl)-8-methyl-6-nonenamide #; Spectrum3_001449; HY-10448; (E)-N-[(4-Hydroxy-3-methoxyphenyl)-methyl]-8-methyl-6-nonenamide; BSPBio_002917; ST057183; KBio2_005919; ZINC1530575; SPBio_000820; N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide; NCGC00017337-10; CCG-39908; STL372889; N-[(4-hydroxy-3-methoxyphenyl)methyl]-6E-8-methyl-nonenamide; Capsaicin Patch; UPCMLD-DP092:002; NGX-3781; BBL027836; (E)-N-[(4-hydroxy-3-methoxy-phenyl)methyl]-8-methyl-non-6-enamide; Capsaicin (8-Methyl-N-vanillyl-6-nonenamide); 912457-62-6; HMS2089N11; Capsaicin; epsilon-capsaicin; (E)-N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide; NGX-4010; 6-Nonenamide, 8-methyl-N-vanillyl-, (E)- (8CI); KBioSS_000268; 21748_FLUKA; Citrus Aurantium Extract; KBio2_005404; TNP00277; trans-Capsaicin; CHEBI:3374; Capsaicin(Qutenza); CITRUS AURANTIUM PE; CAPSAICIN (2444-46-4 NONIVAMIDE (SYNTHETIC CAPSAICIN)); N1667; BSPBio_000957; 4-13-00-02588 (Beilstein Handbook Reference); BRD-K37056290-001-01-1; KBio2_003351; NCGC00090853-07; SMP2_000337; NINDS_000354; Isodecenoate; DSSTox_CID_241; ALGRX 4975; 404-86-4; CAPSAICINOIDS;Vanilloid;campsiol;capsaicin C18H27NO3 305.41 CC(C)C=CCCCCC(=O)NCC1=CC(=C(C=C1)O)OC
TCMBANKIN059684 Vitamin E β- C29H50O2 430.79 CC1=C(C(=C2CCC(OC2=C1C)(C)CCCC(C)CCCC(C)CCCC(C)C)C)O
TCMBANKIN059746 α-tocopherol C29H50O2 430.7 g/mol CC1=C(C2=C(CCC(O2)(C)CCCC(C)CCCC(C)CCCC(C)C)C(=C1O)C)C
TCMBANKIN060264 rutin C27H30O16 610.5 g/mol CC1C(C(C(C(O1)OCC2C(C(C(C(O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)O)C5=CC(=C(C=C5)O)O)O)O)O)O)O)O
TCMBANKIN060497 dioscin C45H72O16 869.04 CC1CCC2(C(C3C(O2)CC4C3(CCC5C4CC=C6C5(CCC(C6)OC7C(C(C(C(O7)CO)OC8C(C(C(C(O8)C)O)O)O)O)OC9C(C(C(C(O9)C)O)O)O)C)C)C)OC1
TCMBANKIN060645 lovastatin C24H36O5 404.5 g/mol CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C
TCMBANKIN061570 curcumin (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one; C10443; BSPBio_003590; NCGC00095321-01; Curcumin; KBio3_003004; InChI=1/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-13,22,24-25H,1-2H3/b7-3+,8-4+,16-13; curcumin ; diferuloylmethane; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one; Kacha haldi; (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one; ZINC00899824; 458-37-7; SDCCGMLS-0066836.P001; SCHEMBL2622435; Spectrum3_001990; DivK1c_006683; KBio1_001627; SpecPlus_000587; SPBio_001728; Spectrum2_001714; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one; NSC32982; Turmeric oleoresin (79%-85% curcumin); Yellow Root; Halad; Diferaloylmethane; kachs haldi; safra d'inde; Curcumin, 95% (total curcuminoid content), from Turmeric rhizome; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; GTPL7000; Turmeric, oleoresin; CI 75300; MFCD00008365; curcuma longa l. root oil hydrodistilled; DSSTox_CID_1421; NSC-687842; C21H20O6; Merita earth; NCGC00017159-11; 1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; NCGC00017159-06; I06-2497; BDBM50140172; I14-19358; MLS001148449; LS-125; NCGC00023332-04; SCHEMBL8441; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,4,6-heptatrien-3-one; BIDD:ER0479; 458-37-7; Turmeric root oil; Tox21_111505; BDBM50067040; 1790-EP2308861A1; Safran d'Inde; Turmeric oil (Curcuma longa L.); NSC 687842; Tumeric yellow; NCGC00017159-05; Curcuma oil; (1E,6E)-1,7-bis[4-hydroxy-3-(methyloxy)phenyl]hepta-1,6-diene-3,5-dione; 2,7-Nonadiene-4,6-dione, 1,9-bis(4-hydroxy-3-methoxyphenyl)-; EINECS 207-280-5; 15845-47-3; E 100; Curcuma longa l. oleoresin; Curcuma longa l. root oleoresin; SR-01000000149-2; NCGC00017159-10; D0H8LC; HMS3649K06; Turmeric oleoresin; Orange Root; Curcumin (Natural); Indian saffron; Curcumin, United States Pharmacopeia (USP) Reference Standard; NCGC00017159-07; CCG-36107; Curcumin solution, ~0.1 % (w/v) (in ethanol with 2M HCl (99:1 v/v)), for TLC derivatization; 5-Hydroxy-1,7-bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,4,6-trien-3-one; Curcurmin; 1,5-Di(vanillyliden)acetylaceton; I06-0010; Natural yellow 3; SMR000058237; cid_969516; Zlut prirodni 3; CHEMBL140; CAS-458-37-7; Curcumin, analytical standard; BG0601; ZX-AT003872; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione #; BCP9000557; Yellow puccoon; Tumeric oleoresin; DB11672; 1,9-Bis(4-hydroxy-3-methoxyphenyl)-2,7-nonadiene-4,6-dione; BG00706978; NSC687842; AC1LJ6T6; SCHEMBL8440; SR-01000000149; Tox21_201116; 1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; J10108; C.I. Natural Yellow 3; (1E,4Z,6E)-5-Hydroxy-1,7-bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,4,6-trien-3-one; Curcumin (synthetic); BIC8500; NCGC00017159-09; CCRIS 5804; NCGC00023332-05; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; W-5038; 1,7-DI(4-HYDROXY-3-METHOXYPHENYL)HEPTA-1,6-DIENE-3; 1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione, (E,E)-; FEMA No. 3086; 1790-EP2305629A1; BB_NC-01422; BC678109; 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-, (E,E)-; WLN: 1OR BQ E1U1V1V1U1R DQ CO1; Yellow Ginger; Diferuloylmethane; BRN 2306965; Bio-0677; AC1Q46A0; 98% curcurmin); cid_5281767; ZINC899824; Oils, galangal; 33171-04-9; (1E,6E)-1,7-bis(3-methoxy-4-oxidanyl-phenyl)hepta-1,6-diene-3,5-dione; curcuma longa l. root oil CO2 extract; Gelbwurz; OR24598; Oil of turmeric; Curcuma oil (Curcuma longa); MLS000069631; 1,5-Divanillyliden-2,4-pentandion; BDBM29532; 1,7-bis(4-hydroxy-3-methoxyphenyl)1,6-heptadiene-3,5-dione; UNII-IT942ZTH98; Yellow, Turmeric; BCP0726000035; Tox21_110803; KB-251224; CU-01000001305-2; Turmeric oil; HMS2233K04; D07SDQ; ST055629; Curcumin, primary pharmaceutical reference standard; CCG-36020; BRD-K07572174-001-19-6; MolPort-001-763-682; DSSTox_GSID_31077; DSSTox_RID_78861; Turmeric; 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-; NSC-32982; Kacha haldi; HY-N0005; Kurkumin [Czech]; Haldar; PREVENTION 4 (CURCUMIN) (SEE ALSO TUMERIC, OLEORESIN (10105-J)); (1Z,6E)-1,7-Bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,6-diene-3,5-dione; Turmeric (>98% curcurmin); GP8291; M212; Zlut prirodni 3 [Czech]; VFLDPWHFBUODDF-FCXRPNKRSA-N; LS-2189; Turmeric yellow; Turmeric extract (Curcuma longa L.); Curcumin; 1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; TR-032605; Curcuma longa l. root oil; FEMA No. 3085; curouma; Tu rmeric root oil; Opera_ID_1627; AC-24238; 73729-23-4; Halud; 1,7-Bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,6-diene-3,5-dione; RTR-032605; Yo-Kin; NCGC00023332-03; trans,trans-Curcumin; Curcuma longa l. oil; 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-, (1E,6E)-; IT942ZTH98; (E,E)-1,7-bis(4-Hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; diferuloylmethan; cMAP_000052; N1839; 1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; BG01656528; Curcuma; CCRIS 3257; Diferulylmethane; Curcumin, >=94% (curcuminoid content), >=80% (Curcumin); NCGC00017159-04; SC-17381; BRD-K07572174-001-22-0; turmeric root oil hydrodistilled; Oils, curcuma; 458C377; Hydrastis; AK316302; Haldar, Souchet; Natural Yellow3; 4-08-00-03697 (Beilstein Handbook Reference); E 100 (Dye); 1,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-; CS-1490; Indian turmeric; (1E,6E)-1,7-Bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,6-diene-3,5-dione; ((E,E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione); Kurkumin; Curcumin I; Souchet; (1E,6E)-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,6-diene-3,5-dione; HSDB 4334; Haidr; NCI-C61325; BBL027711; Golden seal; SCHEMBL13521974; CC0179; 1,3-Di(3-methoxy-4-hydroxystyryl)propanedial; Terra Merita; NCGC00258668-01; SBB006495; Curcumin, matrix substance for MALDI-MS, >=99.5% (HPLC); STL371943; AN-23454; CURCUMIN (SEE ALSO TUMERIC, OLEORESIN (10105-J)); 8024-37-1; Curcuma longa oils; 91884-86-5; AKOS001305497; BRD-K07572174-001-02-2; Turmeric extract; TURMERIC, OLEORESIN (CURCUMIN) (SEE ALSO CURCURMIN (458-37-7)); CI Natural Yellow 3; Cucurmin; CHEBI:3962; DTXSID8031077; DB-002681; Curcumine; Turmeric root oleoresin; curcumin; turmeric root oil CO2 extract; Curcumin, from Curcuma longa (Turmeric), powder; NCGC00017159-12; 79257-48-0; C.I. 75300; 1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadien-3,5-dione; NSC 32982; SR-01000000149-5, curcumine;curcumin IC21H20O6 368.4 g/mol COC1=C(C=CC(=C1)C=CC(=O)CC(=O)C=CC2=CC(=C(C=C2)O)OC)O

   靶点对应的疾病
疾病ID 疾病名 MeSH名 HPO名 UMLS名 疾病类型
TCMBANKDI000009 Neoplasms Abnormality of the nervous system; Neoplasm Neoplastic Process disease
TCMBANKDI000023 Skin and Connective Tissue Diseases; Immune System Diseases Abnormality of the immune system Disease or Syndrome disease
TCMBANKDI000035 Digestive System Diseases; Infections - Disease or Syndrome disease
TCMBANKDI000054 Nervous System Diseases; Mental Disorders Abnormality of the nervous system Disease or Syndrome disease
TCMBANKDI000061 Digestive System Diseases; Neoplasms Abnormality of the digestive system; Neoplasm Neoplastic Process group
TCMBANKDI000071 Digestive System Diseases; Chemically-Induced Disorders - Disease or Syndrome disease
TCMBANKDI000074 Pathological Conditions, Signs and Symptoms; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases - Disease or Syndrome disease
TCMBANKDI000076 Neoplasms - Neoplastic Process group
TCMBANKDI000078 Neoplasms; Skin and Connective Tissue Diseases Abnormality of the integument; Neoplasm Neoplastic Process group
TCMBANKDI000088 Neoplasms; Respiratory Tract Diseases Neoplasm; Abnormality of the respiratory system Neoplastic Process group
TCMBANKDI000092 Respiratory Tract Diseases Abnormality of the respiratory system Disease or Syndrome disease
TCMBANKDI000166 - - Neoplastic Process disease
TCMBANKDI000171 Nervous System Diseases; Cardiovascular Diseases - Disease or Syndrome disease
TCMBANKDI000371 Pathological Conditions, Signs and Symptoms; Eye Diseases; Nervous System Diseases; Wounds and Injuries - Disease or Syndrome phenotype
TCMBANKDI000432 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Neoplasms; Nutritional and Metabolic Diseases; Skin and Connective Tissue Diseases - Congenital Abnormality disease
TCMBANKDI000891 Neoplasms; Respiratory Tract Diseases Neoplasm; Abnormality of the respiratory system Neoplastic Process disease
TCMBANKDI001180 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases; Musculoskeletal Diseases; Nervous System Diseases - Disease or Syndrome disease
TCMBANKDI001279 Pathological Conditions, Signs and Symptoms; Nervous System Diseases; Cardiovascular Diseases Abnormality of the nervous system; Abnormality of blood and blood-forming tissues; Abnormality of the cardiovascular system Disease or Syndrome disease
TCMBANKDI001299 Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases; Cardiovascular Diseases Abnormality of the genitourinary system Disease or Syndrome disease
TCMBANKDI001567 Immune System Diseases; Hemic and Lymphatic Diseases - Neoplastic Process disease
TCMBANKDI001706 Musculoskeletal Diseases Abnormality of limbs; Abnormality of the skeletal system Disease or Syndrome disease
TCMBANKDI001965 Immune System Diseases - Disease or Syndrome disease
TCMBANKDI002231 Digestive System Diseases Abnormality of the digestive system Disease or Syndrome disease
TCMBANKDI002287 Neoplasms; Hemic and Lymphatic Diseases - Neoplastic Process group
TCMBANKDI002297 Infections - Disease or Syndrome disease
TCMBANKDI002974 Neoplasms - Neoplastic Process disease
TCMBANKDI003248 Nutritional and Metabolic Diseases; Endocrine System Diseases Abnormality of metabolism/homeostasis; Abnormality of the endocrine system Disease or Syndrome disease
TCMBANKDI003353 Pathological Conditions, Signs and Symptoms; Neoplasms - Neoplastic Process phenotype
TCMBANKDI004201 Digestive System Diseases; Wounds and Injuries - Injury or Poisoning disease
TCMBANKDI004344 Nervous System Diseases; Endocrine System Diseases - Disease or Syndrome group
TCMBANKDI004450 - Abnormality of metabolism/homeostasis; Abnormal cellular phenotype Anatomical Abnormality disease
TCMBANKDI004576 Mental Disorders - Mental or Behavioral Dysfunction disease
TCMBANKDI004728 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Neoplasms; Nutritional and Metabolic Diseases; Skin and Connective Tissue Diseases - Disease or Syndrome disease
TCMBANKDI004844 Digestive System Diseases Abnormality of the digestive system Disease or Syndrome disease
TCMBANKDI004958 Neoplasms; Hemic and Lymphatic Diseases - Neoplastic Process disease
TCMBANKDI005822 Infections - Disease or Syndrome disease
TCMBANKDI006055 Pathological Conditions, Signs and Symptoms; Neoplasms - Neoplastic Process disease
TCMBANKDI006156 Digestive System Diseases; Cardiovascular Diseases - Disease or Syndrome disease
TCMBANKDI006328 - Abnormality of the genitourinary system Disease or Syndrome phenotype
TCMBANKDI006450 Stomatognathic Diseases - Disease or Syndrome disease
TCMBANKDI006612 Neoplasms; Female Urogenital Diseases and Pregnancy Complications Abnormality of the genitourinary system; Neoplasm Neoplastic Process disease
TCMBANKDI006641 Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases - Pathologic Function phenotype
TCMBANKDI007091 Neoplasms - Neoplastic Process phenotype
TCMBANKDI007135 - - Disease or Syndrome disease
TCMBANKDI007362 Pathological Conditions, Signs and Symptoms; Nutritional and Metabolic Diseases - Disease or Syndrome disease
TCMBANKDI007737 Pathological Conditions, Signs and Symptoms; Neoplasms - Neoplastic Process disease
TCMBANKDI008043 Cardiovascular Diseases Abnormality of the cardiovascular system Anatomical Abnormality disease
TCMBANKDI009099 Nutritional and Metabolic Diseases; Endocrine System Diseases - Experimental Model of Disease disease
TCMBANKDI009127 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases; Nervous System Diseases - Disease or Syndrome disease
TCMBANKDI009231 Pathological Conditions, Signs and Symptoms; Infections Abnormality of the immune system Disease or Syndrome disease
TCMBANKDI009278 Mental Disorders - Mental or Behavioral Dysfunction group
TCMBANKDI009571 Cardiovascular Diseases Abnormality of the cardiovascular system Disease or Syndrome disease
TCMBANKDI009657 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Cardiovascular Diseases Abnormality of the cardiovascular system Congenital Abnormality group
TCMBANKDI009702 Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases Abnormality of the cardiovascular system Disease or Syndrome phenotype
TCMBANKDI009912 Pathological Conditions, Signs and Symptoms Abnormality of metabolism/homeostasis Sign or Symptom phenotype
TCMBANKDI009951 Nutritional and Metabolic Diseases; Musculoskeletal Diseases Abnormality of the skeletal system Disease or Syndrome disease
TCMBANKDI010048 Infections; Respiratory Tract Diseases Abnormality of the immune system; Abnormality of the respiratory system Disease or Syndrome disease
TCMBANKDI010160 Respiratory Tract Diseases Abnormality of the respiratory system Disease or Syndrome group
TCMBANKDI010395 Neoplasms - Neoplastic Process disease
TCMBANKDI011173 Neoplasms - Neoplastic Process disease
TCMBANKDI011174 Infections - Disease or Syndrome group
TCMBANKDI011229 Stomatognathic Diseases Abnormality of the immune system; Abnormality of head or neck Disease or Syndrome disease
TCMBANKDI011264 Pathological Conditions, Signs and Symptoms; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases; Stomatognathic Diseases; Otorhinolaryngologic Diseases - Disease or Syndrome disease
TCMBANKDI011458 Nutritional and Metabolic Diseases - Disease or Syndrome disease
TCMBANKDI011480 Cardiovascular Diseases Abnormality of the cardiovascular system Congenital Abnormality disease
TCMBANKDI011557 Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases Abnormality of the cardiovascular system Disease or Syndrome disease
TCMBANKDI011608 Neoplasms; Nervous System Diseases - Neoplastic Process disease
TCMBANKDI011743 Neoplasms; Skin and Connective Tissue Diseases Neoplasm; Abnormality of the breast Neoplastic Process group
TCMBANKDI011827 Digestive System Diseases Abnormality of the digestive system; Abnormality of the immune system Disease or Syndrome disease
TCMBANKDI011857 Pathological Conditions, Signs and Symptoms; Nervous System Diseases; Behavior and Behavior Mechanisms Abnormality of the nervous system Mental or Behavioral Dysfunction disease
TCMBANKDI011912 Neoplasms - Neoplastic Process disease
TCMBANKDI012119 Pathological Conditions, Signs and Symptoms Abnormality of the nervous system Cell or Molecular Dysfunction phenotype
TCMBANKDI012932 Infections; Immune System Diseases - Disease or Syndrome group
TCMBANKDI012976 Neoplasms; Stomatognathic Diseases - Neoplastic Process disease
TCMBANKDI013215 Nutritional and Metabolic Diseases; Skin and Connective Tissue Diseases; Musculoskeletal Diseases - Disease or Syndrome disease
TCMBANKDI013321 Skin and Connective Tissue Diseases - Disease or Syndrome disease
TCMBANKDI013347 Pathological Conditions, Signs and Symptoms Abnormality of metabolism/homeostasis Disease or Syndrome disease
TCMBANKDI013495 Hemic and Lymphatic Diseases Neoplasm; Abnormality of blood and blood-forming tissues Neoplastic Process group
TCMBANKDI013541 Cardiovascular Diseases - Disease or Syndrome group
TCMBANKDI013772 - - Disease or Syndrome disease
TCMBANKDI014088 Respiratory Tract Diseases; Cardiovascular Diseases Abnormality of the respiratory system; Abnormality of the cardiovascular system Disease or Syndrome disease
TCMBANKDI014161 Stomatognathic Diseases Abnormality of the immune system; Abnormality of head or neck Disease or Syndrome group
TCMBANKDI014645 Pathological Conditions, Signs and Symptoms Abnormality of the digestive system Disease or Syndrome disease
TCMBANKDI014748 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases - Disease or Syndrome disease
TCMBANKDI014974 Female Urogenital Diseases and Pregnancy Complications - Disease or Syndrome disease
TCMBANKDI015238 Musculoskeletal Diseases - Disease or Syndrome disease
TCMBANKDI015310 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nervous System Diseases - Disease or Syndrome disease
TCMBANKDI015452 Neoplasms; Endocrine System Diseases Abnormality of the endocrine system; Neoplasm Neoplastic Process disease
TCMBANKDI015485 Mental Disorders Abnormality of the nervous system Mental or Behavioral Dysfunction disease
TCMBANKDI016010 - - Disease or Syndrome disease
TCMBANKDI016026 Neoplasms; Eye Diseases Neoplasm; Abnormality of the eye Neoplastic Process disease
TCMBANKDI016439 Nervous System Diseases - Disease or Syndrome disease
TCMBANKDI016612 Mental Disorders Abnormality of the nervous system Mental or Behavioral Dysfunction phenotype
TCMBANKDI016890 Digestive System Diseases; Neoplasms - Neoplastic Process disease
TCMBANKDI016946 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Digestive System Diseases; Respiratory Tract Diseases - Disease or Syndrome disease
TCMBANKDI017024 Neoplasms; Respiratory Tract Diseases - Neoplastic Process disease
TCMBANKDI017642 Neoplasms Abnormality of the integument; Neoplasm Neoplastic Process disease
TCMBANKDI017952 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases; Nervous System Diseases - Disease or Syndrome disease
TCMBANKDI018017 Pathological Conditions, Signs and Symptoms; Nervous System Diseases - Sign or Symptom phenotype
TCMBANKDI018635 Digestive System Diseases Abnormality of the digestive system Disease or Syndrome disease
TCMBANKDI018680 Eye Diseases; Immune System Diseases; Endocrine System Diseases Abnormality of the endocrine system Disease or Syndrome disease
TCMBANKDI018731 Digestive System Diseases Abnormality of the digestive system Disease or Syndrome disease
TCMBANKDI019825 Neoplasms - Neoplastic Process disease
TCMBANKDI019879 Digestive System Diseases; Neoplasms; Endocrine System Diseases - Neoplastic Process disease
TCMBANKDI020257 Cardiovascular Diseases - Disease or Syndrome disease
TCMBANKDI020278 Eye Diseases - Disease or Syndrome disease
TCMBANKDI020451 Neoplasms - Neoplastic Process disease
TCMBANKDI020584 Nutritional and Metabolic Diseases Abnormality of metabolism/homeostasis Disease or Syndrome disease
TCMBANKDI020603 Pathological Conditions, Signs and Symptoms - Anatomical Abnormality phenotype
TCMBANKDI020794 Nutritional and Metabolic Diseases Abnormality of metabolism/homeostasis Disease or Syndrome disease
TCMBANKDI021272 Cardiovascular Diseases - Pathologic Function phenotype
TCMBANKDI021831 Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases Abnormality of the endocrine system Disease or Syndrome disease
TCMBANKDI022322 - - Disease or Syndrome disease
TCMBANKDI023013 - - Disease or Syndrome disease
TCMBANKDI023140 Neoplasms; Endocrine System Diseases Abnormality of the endocrine system; Neoplasm Neoplastic Process disease
TCMBANKDI023464 Nervous System Diseases Abnormality of the nervous system Disease or Syndrome disease
TCMBANKDI023498 Skin and Connective Tissue Diseases; Musculoskeletal Diseases - Disease or Syndrome disease
TCMBANKDI023834 Nervous System Diseases - Disease or Syndrome group
TCMBANKDI024262 - - Neoplastic Process phenotype
TCMBANKDI024535 Neoplasms; Respiratory Tract Diseases Neoplasm; Abnormality of the respiratory system Neoplastic Process disease
TCMBANKDI024839 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Neoplasms; Nutritional and Metabolic Diseases; Skin and Connective Tissue Diseases - Disease or Syndrome disease
TCMBANKDI024875 Nutritional and Metabolic Diseases; Musculoskeletal Diseases - Disease or Syndrome disease
TCMBANKDI024930 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases - Disease or Syndrome disease
TCMBANKDI025141 Endocrine System Diseases Abnormality of the endocrine system; Abnormality of the immune system Disease or Syndrome disease
TCMBANKDI025194 - - Finding disease
TCMBANKDI025401 Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases - Pathologic Function phenotype
TCMBANKDI025420 Digestive System Diseases; Neoplasms Abnormality of the digestive system; Neoplasm Neoplastic Process disease
TCMBANKDI026153 Digestive System Diseases - Disease or Syndrome disease
TCMBANKDI026277 Neoplasms Neoplasm Neoplastic Process disease
TCMBANKDI027026 Neoplasms; Skin and Connective Tissue Diseases - Neoplastic Process disease
TCMBANKDI027040 Immune System Diseases - Disease or Syndrome disease
TCMBANKDI027339 Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases Neoplasm; Abnormality of blood and blood-forming tissues Neoplastic Process disease
TCMBANKDI027628 Pathological Conditions, Signs and Symptoms; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases; Skin and Connective Tissue Diseases - Disease or Syndrome disease
TCMBANKDI027682 Digestive System Diseases; Neoplasms Abnormality of the digestive system; Neoplasm Neoplastic Process disease
TCMBANKDI027853 Infections; Immune System Diseases - Disease or Syndrome disease
TCMBANKDI028064 - - Disease or Syndrome disease
TCMBANKDI028459 Congenital, Hereditary, and Neonatal Diseases and Abnormalities Abnormality of the digestive system; Abnormality of the cardiovascular system; Growth abnormality Congenital Abnormality disease
TCMBANKDI028619 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Immune System Diseases - Disease or Syndrome disease
TCMBANKDI028663 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases - Disease or Syndrome; Congenital Abnormality disease
TCMBANKDI028799 Eye Diseases - Disease or Syndrome disease
TCMBANKDI029321 Cardiovascular Diseases - Disease or Syndrome group
TCMBANKDI029791 Nutritional and Metabolic Diseases - Disease or Syndrome phenotype
TCMBANKDI029899 Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases Neoplasm; Abnormality of blood and blood-forming tissues Neoplastic Process group
TCMBANKDI030313 Neoplasms; Male Urogenital Diseases - Neoplastic Process disease
TCMBANKDI030540 Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Endocrine System Diseases Abnormality of the genitourinary system; Neoplasm Neoplastic Process disease
TCMBANKDI030653 Neoplasms - Neoplastic Process disease
TCMBANKDI030716 Pathological Conditions, Signs and Symptoms; Nervous System Diseases Abnormality of the nervous system Finding phenotype
TCMBANKDI030870 Neoplasms - Neoplastic Process disease
TCMBANKDI031139 Nervous System Diseases; Cardiovascular Diseases - Disease or Syndrome disease
TCMBANKDI031189 Neoplasms Neoplasm; Abnormality of the respiratory system Neoplastic Process disease
TCMBANKDI031190 Cardiovascular Diseases - Pathologic Function phenotype
TCMBANKDI031192 Neoplasms; Male Urogenital Diseases - Neoplastic Process disease
TCMBANKDI031522 Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases Abnormality of the genitourinary system; Neoplasm Neoplastic Process disease
TCMBANKDI031523 Hemic and Lymphatic Diseases Abnormality of blood and blood-forming tissues Disease or Syndrome disease
TCMBANKDI032189 Respiratory Tract Diseases; Wounds and Injuries - Disease or Syndrome disease
TCMBANKDI032222 Nervous System Diseases; Mental Disorders - Mental or Behavioral Dysfunction disease
TCMBANKDI032417 Mental Disorders Abnormality of the nervous system Mental or Behavioral Dysfunction disease
TCMBANKDI032472 Pathological Conditions, Signs and Symptoms; Neoplasms; Nervous System Diseases - Neoplastic Process disease
TCMBANKDI032496 Nutritional and Metabolic Diseases Abnormality of metabolism/homeostasis Disease or Syndrome disease
TCMBANKDI032498 Nutritional and Metabolic Diseases Abnormality of metabolism/homeostasis; Abnormality of the endocrine system Disease or Syndrome disease